Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter studyFumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa et al.|International Journal of Urology|2024Cited by 20
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Takahiro Kimura, Katsuki Muramoto et al.|The Prostate|2024Cited by 19
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Takahiro Kimura, Kojiro Tashiro et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 11
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective studyKatsuki Muramoto, Takahiro Kimura, Fumihiko Urabe et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 7
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter studyFumihiko Urabe, Takahiro Kimura, Shingo Hatakeyama et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 7